An SSMM-Informed Clinical Decision Architecture for Staged Laser Iris Depigmentation

Background: Laser iris depigmentation presents distinct questions of initial patient suitability, eye-specific safety, pigmentary response, and authorization of subsequent staged exposure. These decisions are often described together, although their information requirements and consequences are not interchangeable. Objective: To specify an auditable clinical decision architecture that integrates existing Lumineyes™ program eligibility policy, four-domain anterior-segment reassessment, longitudinal response documentation, and independent physician authorization while retaining explicit boundaries between clinical practice, conceptual frameworks, and unvalidated mechanisms. Methods: This technical note synthesizes the publicly available Lumineyes™ Laser Iris Depigmentation Clinical Practice Standard v1.0 (Zenodo DOI: 10.5281/zenodo.24256204), previously proposed Selective Stromal Melanin Modulation (SSMM) and Lumineyes Anterior-Segment Safety Staging (L-SAFE) frameworks, and selected ophthalmic clinical and methodological literature. Four decision gates, a minimum linked record, withholding and sequence-closure rules, and a staged external-validation plan were specified. No new patient-level dataset, clinician-reliability experiment, or treatment-outcome analysis was performed. Proposed output: The architecture separates (A) patient- and eye-level eligibility, (B) a complete eye-specific safety checkpoint, (C) documentation of prior-stage pigmentary and non-pigmentary response, and (D) an explicit stage-specific authorization decision. An S0 (READY) safety state does not itself authorize treatment. Incomplete mandatory observations cannot establish S0; S1 and S2 withhold additional exposure, whereas S3 terminates the current treatment sequence. A linked record preserves prior events, medication context, clinical rationale, and follow-up disposition. Conclusion: The contribution is a traceable decision and recording specification, not a validated safety or effectiveness algorithm. Feasibility, inter-rater reproducibility, independent outcome association, and external utility must be evaluated before any clinical benefit is inferred.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-17
DOI
https://doi.org/10.20944/preprints202611.1650.v1
Primary Topic
Ocular and Laser Science Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

An SSMM-Informed Clinical Decision Architecture for Staged Laser Iris Depigmentation

Mete Mustafa
6 links
Preprints.org
Ocular and Laser Science Research
preprint

An SSMM-Informed Clinical Decision Architecture for Staged Laser Iris Depigmentation

Mete Mustafa
preprint en

Abstract

Background: Laser iris depigmentation presents distinct questions of initial patient suitability, eye-specific safety, pigmentary response, and authorization of subsequent staged exposure. These decisions are often described together, although their information requirements and consequences are not interchangeable. Objective: To specify an auditable clinical decision architecture that integrates existing Lumineyes™ program eligibility policy, four-domain anterior-segment reassessment, longitudinal response documentation, and independent physician authorization while retaining explicit boundaries between clinical practice, conceptual frameworks, and unvalidated mechanisms. Methods: This technical note synthesizes the publicly available Lumineyes™ Laser Iris Depigmentation Clinical Practice Standard v1.0 (Zenodo DOI: 10.5281/zenodo.24256204), previously proposed Selective Stromal Melanin Modulation (SSMM) and Lumineyes Anterior-Segment Safety Staging (L-SAFE) frameworks, and selected ophthalmic clinical and methodological literature. Four decision gates, a minimum linked record, withholding and sequence-closure rules, and a staged external-validation plan were specified. No new patient-level dataset, clinician-reliability experiment, or treatment-outcome analysis was performed. Proposed output: The architecture separates (A) patient- and eye-level eligibility, (B) a complete eye-specific safety checkpoint, (C) documentation of prior-stage pigmentary and non-pigmentary response, and (D) an explicit stage-specific authorization decision. An S0 (READY) safety state does not itself authorize treatment. Incomplete mandatory observations cannot establish S0; S1 and S2 withhold additional exposure, whereas S3 terminates the current treatment sequence. A linked record preserves prior events, medication context, clinical rationale, and follow-up disposition. Conclusion: The contribution is a traceable decision and recording specification, not a validated safety or effectiveness algorithm. Feasibility, inter-rater reproducibility, independent outcome association, and external utility must be evaluated before any clinical benefit is inferred.

Preprints.org
Good health and well-being
Ocular and Laser Science Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon